In which clinical situations should esaxerenone be preferred over spironolactone (aldactone) for hypertension or heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Esaxerenone vs Spironolactone (Aldactone): Clinical Selection

Spironolactone (Aldactone) remains the preferred mineralocorticoid receptor antagonist for hypertension and heart failure in Western clinical practice, as it has the strongest evidence for mortality reduction and is recommended by current guidelines, while esaxerenone is not mentioned in major international guidelines and lacks robust cardiovascular outcome data. 1, 2, 3

Guideline-Based Recommendations

For Resistant Hypertension

Spironolactone is the first-line fourth agent when blood pressure remains ≥130/80 mmHg despite optimal doses of ACE inhibitor/ARB + calcium channel blocker + thiazide-like diuretic 2. The 2025 AHA/ACC guidelines specifically recommend spironolactone 25-50 mg/day, which reduces 24-hour systolic BP by 6.6-8.7 mmHg compared to placebo 2. The 2024 ESC guidelines similarly prioritize spironolactone addition for resistant hypertension 1.

Esaxerenone is not mentioned in either major guideline 1, 2, reflecting its limited adoption outside Japan and absence of large-scale cardiovascular outcome trials.

For Heart Failure with Reduced Ejection Fraction (HFrEF)

Spironolactone is FDA-approved and guideline-recommended for NYHA Class III-IV heart failure with reduced ejection fraction to increase survival, manage edema, and reduce hospitalizations 3. The landmark RALES trial demonstrated a 30% reduction in all-cause mortality (p<0.001) 3.

Both guidelines recommend mineralocorticoid receptor antagonists (MRAs) as part of foundational HFrEF therapy 1, 2, but spironolactone has the mortality data that esaxerenone lacks.

For Heart Failure with Preserved Ejection Fraction (HFpEF)

The 2024 ESC guidelines note that ARBs and/or MRAs "may be considered" to reduce heart failure hospitalizations in symptomatic HFpEF patients with BP above target 1. However, no MRA has proven superiority for HFpEF mortality reduction 4.

When Esaxerenone May Be Considered

Specific Clinical Scenarios (Based on Limited Evidence)

1. Intolerance to Spironolactone's Antiandrogenic Effects

  • Gynecomastia, breast tenderness, or sexual dysfunction occur in 4-40% of patients on spironolactone 2
  • Esaxerenone, as a non-steroidal MRA, avoids these effects 5
  • However, eplerenone (also steroidal but more selective) is the guideline-recommended alternative 1, 2

2. Combination Therapy in Hypertension with Chronic Heart Failure One prospective study (n=156) showed that switching from eplerenone to esaxerenone in patients with chronic heart failure and hypertension resulted in:

  • Significant BP reduction (both systolic and diastolic, p<0.001)
  • Decreased BNP at 3 and 6 months (p=0.008 and p=0.002)
  • Improved renal function (decreased creatinine, increased eGFR)
  • Reduced urinary albumin-to-creatinine ratio 5

Critical limitation: This was an uncontrolled switch study without randomization or comparison to continued eplerenone therapy, making it impossible to determine if benefits were due to esaxerenone's superiority or simply optimization of MRA therapy.

3. Theoretical Advantage in Hyperkalemia Risk Esaxerenone may have different potassium-handling properties 6, but no head-to-head trials demonstrate lower hyperkalemia rates compared to spironolactone at equivalent doses.

Evidence Hierarchy and Quality Assessment

Spironolactone's Evidence Base

  • Mortality reduction: RALES trial (30% reduction, p<0.001) 3
  • Resistant hypertension: PATHWAY-2 trial showing superiority over placebo and other agents 7
  • FDA-approved indications: Heart failure, hypertension, edema, primary hyperaldosteronism 3
  • Guideline support: Class I recommendations in major guidelines 1, 2

Esaxerenone's Evidence Base

  • No cardiovascular outcome trials demonstrating mortality or morbidity reduction
  • One small prospective study (n=156) showing physiological improvements when switching from eplerenone 5
  • Exploratory studies examining LVH regression (ESES-LVH protocol published but results not yet available) 8
  • Not mentioned in 2024 ESC or 2025 AHA/ACC guidelines 1, 2

Practical Algorithm for MRA Selection

Step 1: Determine Primary Indication

  • HFrEF (NYHA III-IV): Spironolactone 25 mg daily, titrate to 50 mg if tolerated 3
  • Resistant hypertension: Spironolactone 25-50 mg daily as fourth agent 2
  • Primary hyperaldosteronism: Spironolactone (FDA-approved) 3

Step 2: Assess Tolerability Issues

  • If gynecomastia/sexual dysfunction develops: Switch to eplerenone (guideline-recommended alternative) 1, 2
  • If hyperkalemia occurs: Reduce dose, optimize diet, consider potassium binders, or switch to amiloride 2

Step 3: Consider Esaxerenone Only If:

  • Patient is in a region where esaxerenone is available (primarily Japan)
  • AND patient has failed or is intolerant to both spironolactone and eplerenone
  • AND close monitoring for efficacy and safety is feasible
  • Recognize this is off-guideline use with limited outcome data

Critical Caveats

Hyperkalemia monitoring is mandatory with any MRA:

  • Check potassium at baseline, 1 week, 1 month, then quarterly 6
  • Higher risk with eGFR <45 mL/min/1.73 m², diabetes, age >70, or concurrent RAAS inhibitors 6
  • Discontinue if potassium >5.5 mEq/L 2

Comparative effectiveness data is lacking: No randomized trials directly compare esaxerenone to spironolactone for cardiovascular outcomes. The 2025 meta-analysis showed spironolactone had the most protective effect in non-HF populations (HR 0.40) and diabetes (HR 0.57), while finerenone performed better in HF populations 9. Esaxerenone was not included in this analysis, highlighting its limited evidence base.

Cost and availability: Spironolactone is generic, widely available, and inexpensive. Esaxerenone availability is limited primarily to Japan, making it impractical for most Western clinicians.

Bottom Line

Use spironolactone as the default MRA for hypertension and heart failure based on robust mortality data, FDA approval, and guideline recommendations 1, 2, 3. Switch to eplerenone if antiandrogenic side effects occur 1, 2. Esaxerenone lacks the evidence base to recommend it over established agents and should only be considered in exceptional circumstances where both spironolactone and eplerenone have failed, recognizing this represents off-guideline therapy with uncertain cardiovascular outcomes 5, 8.

References

Research

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.

Hypertension research : official journal of the Japanese Society of Hypertension, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.